<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904735</url>
  </required_header>
  <id_info>
    <org_study_id>SRSI-GICNO-08-002</org_study_id>
    <secondary_id>CDR0000641101</secondary_id>
    <secondary_id>NOVARTIS-SRSI-GICNO-08-002</secondary_id>
    <nct_id>NCT00904735</nct_id>
  </id_info>
  <brief_title>Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma</brief_title>
  <official_title>IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico H. San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. It is not yet known whether hydroxyurea is more effective when given alone&#xD;
      or together with imatinib mesylate in treating patients with meningioma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well hydroxyurea works compared with&#xD;
      giving hydroxyurea together with imatinib mesylate in treating patients with recurrent or&#xD;
      progressive meningioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the progression-free survival of patients with recurrent or progressive&#xD;
           meningiomas treated with hydroxyurea with vs without imatinib mesylate after surgery and&#xD;
           radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival, and response rate of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to WHO grade (I vs&#xD;
      II-III). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once&#xD;
           daily in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral hydroxyurea twice daily in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival, defined as ≥ 25% increase in tumor volume or new tumor on MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate according to MacDonald criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v. 3.0</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxyurea</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosed with meningioma&#xD;
&#xD;
               -  WHO grade I-III&#xD;
&#xD;
          -  Recurrent or progressive disease after prior surgery and radiotherapy, or radiosurgery&#xD;
&#xD;
          -  Not amenable to further surgery&#xD;
&#xD;
          -  No optic nerve sheet tumor and neurofibromatosis type II&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  ANC &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 mg/dL (transfusion allowed)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT &lt; 2.5 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier method contraception during and for up to&#xD;
             3 months after completion of study therapy&#xD;
&#xD;
          -  No second malignancy&#xD;
&#xD;
          -  No known chronic liver disease (i.e., active hepatitis, cirrhosis)&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No significant history of non-compliance to medical regimens or inability to grant&#xD;
             reliable informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent enzyme-inducing anti-epileptic drugs&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation with warfarin (e.g., Coumadin®)&#xD;
&#xD;
               -  Low-molecular weight heparin (e.g., Lovenox) or heparin allowed&#xD;
&#xD;
               -  Mini-dose Coumadin® (e.g., 1 mg QD) allowed for prophylaxis of central venous&#xD;
                  catheter thrombosis, at the discretion of the treating physician&#xD;
&#xD;
          -  No concurrent acetaminophen (Efferalgan®, Tachipirina®) allowed during imatinib&#xD;
             mesylate administration&#xD;
&#xD;
          -  No other concurrent anticancer agents, including chemotherapy or biological agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alba A. Brandes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Bellaria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Civile Avellino</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-0825-203-232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>I-40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alba A. Brandes, MD</last_name>
      <phone>39-51-622-5102</phone>
      <email>aa.brandes@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-055-427-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-02-2394-2341</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Rovigo</name>
      <address>
        <city>Rovigo</city>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-0425-393-016</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>adult grade I meningioma</keyword>
  <keyword>adult grade II meningioma</keyword>
  <keyword>adult anaplastic meningioma</keyword>
  <keyword>adult papillary meningioma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

